Stefan H. Hohnloser

83.9k total citations · 16 hit papers
422 papers, 31.9k citations indexed

About

Stefan H. Hohnloser is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Internal Medicine. According to data from OpenAlex, Stefan H. Hohnloser has authored 422 papers receiving a total of 31.9k indexed citations (citations by other indexed papers that have themselves been cited), including 410 papers in Cardiology and Cardiovascular Medicine, 35 papers in Surgery and 33 papers in Internal Medicine. Recurrent topics in Stefan H. Hohnloser's work include Cardiac Arrhythmias and Treatments (265 papers), Cardiac electrophysiology and arrhythmias (241 papers) and Atrial Fibrillation Management and Outcomes (224 papers). Stefan H. Hohnloser is often cited by papers focused on Cardiac Arrhythmias and Treatments (265 papers), Cardiac electrophysiology and arrhythmias (241 papers) and Atrial Fibrillation Management and Outcomes (224 papers). Stefan H. Hohnloser collaborates with scholars based in Germany, United States and Canada. Stefan H. Hohnloser's co-authors include Stuart J. Connolly, Jeff S. Healey, Thomas Klingenheben, Carsten W. Israel, Joachim R. Ehrlich, Karl‐Heinz Kück, Markus Zabel, Richard L. Page, Lars Wallentin and Alessandro Capucci and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Stefan H. Hohnloser

411 papers receiving 30.6k citations

Hit Papers

Subclinical Atrial Fibrillation and the Risk o... 2000 2026 2008 2017 2012 2006 2010 2008 2004 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Subclinical Atrial Fibrillation and the Risk of Stroke
    2012 1.4k citations Jeff S. Healey, Stuart J. Connolly et al. profile →
  2. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial
    2006 1.3k citations Stefan H. Hohnloser, Stefan H. Hohnloser et al. profile →
  3. Cardiac-Resynchronization Therapy for Mild-to-Moderate Heart Failure
    2010 1.2k citations Mario Talajic, Stuart J. Connolly et al. profile →
  4. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Death
    2008 1.1k citations Stefan H. Hohnloser et al. Circulation profile →
  5. Prophylactic Use of an Implantable Cardioverter–Defibrillator after Acute Myocardial Infarction
    2004 894 citations Stefan H. Hohnloser, Paul Dorian et al. profile →
  6. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation
    2017 843 citations Christopher P. Cannon, Deepak L. Bhatt et al. profile →
  7. Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation
    2011 822 citations John W. Eikelboom, Lars Wallentin et al. Circulation profile →
  8. Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial
    2000 768 citations Stefan H. Hohnloser et al. profile →
  9. Effect of Dronedarone on Cardiovascular Events in Atrial Fibrillation
    2009 707 citations Stefan H. Hohnloser, Harry J.G.M. Crijns et al. profile →
  10. 2012 Focused Update of the ESC Guidelines for the Management of Atrial Fibrillation
    2012 553 citations A. John Camm, Gregory Y.H. Lip et al. profile →
  11. Baroreflex Sensitivity and Heart Rate Variability in the Identification of Patients at Risk for Life-Threatening Arrhythmias
    2001 540 citations Stefan H. Hohnloser, A. John Camm et al. Circulation profile →
  12. Temporal Relationship Between Subclinical Atrial Fibrillation and Embolic Events
    2014 444 citations Michela Brambatti, Stuart J. Connolly et al. Circulation profile →
  13. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial
    2012 422 citations Stefan H. Hohnloser, Ziad Hijazi et al. European Heart Journal profile →
  14. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT
    2017 363 citations Jeff S. Healey, Harry J.G.M. Crijns et al. European Heart Journal profile →
  15. Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation
    2017 267 citations Stefan H. Hohnloser, Matias Nordaby et al. profile →
  16. The Increasing Role of Rhythm Control in Patients With Atrial Fibrillation
    2022 113 citations A. John Camm, Gerald V. Naccarelli et al. Journal of the American College of Cardiology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stefan H. Hohnloser Germany 90 29.4k 4.0k 3.1k 2.2k 2.1k 422 31.9k
William G. Stevenson United States 80 32.6k 1.1× 2.1k 0.5× 3.2k 1.0× 2.7k 1.2× 2.0k 0.9× 471 35.8k
Stuart J. Connolly Canada 100 42.2k 1.4× 11.2k 2.8× 4.6k 1.5× 2.4k 1.1× 5.2k 2.5× 474 47.0k
Prashanthan Sanders Australia 90 30.4k 1.0× 748 0.2× 3.1k 1.0× 2.1k 1.0× 1.5k 0.7× 692 34.8k
Paulus Kirchhof Germany 75 23.0k 0.8× 3.2k 0.8× 2.3k 0.7× 1.4k 0.6× 2.0k 1.0× 554 26.1k
Günter Breithardt Germany 73 22.9k 0.8× 5.1k 1.3× 2.0k 0.6× 1.6k 0.7× 2.4k 1.1× 415 25.3k
Hans‐Christoph Diener Germany 48 15.0k 0.5× 5.7k 1.4× 1.7k 0.5× 862 0.4× 4.3k 2.0× 175 20.1k
Cynthia M. Tracy United States 49 20.8k 0.7× 2.9k 0.7× 2.2k 0.7× 2.3k 1.1× 1.9k 0.9× 105 22.7k
Jonathan P. Piccini United States 76 24.1k 0.8× 6.9k 1.7× 1.9k 0.6× 1.4k 0.7× 2.9k 1.4× 547 26.3k
Jonathan M. Kalman Australia 78 22.2k 0.8× 671 0.2× 1.9k 0.6× 1.6k 0.7× 1.0k 0.5× 439 24.0k
Katherine T. Murray United States 38 15.8k 0.5× 2.7k 0.7× 1.3k 0.4× 1.1k 0.5× 1.9k 0.9× 108 19.5k

Countries citing papers authored by Stefan H. Hohnloser

Since Specialization
Citations

This map shows the geographic impact of Stefan H. Hohnloser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stefan H. Hohnloser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stefan H. Hohnloser more than expected).

Fields of papers citing papers by Stefan H. Hohnloser

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stefan H. Hohnloser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stefan H. Hohnloser. The network helps show where Stefan H. Hohnloser may publish in the future.

Co-authorship network of co-authors of Stefan H. Hohnloser

This figure shows the co-authorship network connecting the top 25 collaborators of Stefan H. Hohnloser. A scholar is included among the top collaborators of Stefan H. Hohnloser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stefan H. Hohnloser. Stefan H. Hohnloser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Merino, José Luís, Juan Tamargo, Carina Blomström‐Lundqvist, et al.. (2025). Practical compendium of antiarrhythmic drugs: a clinical consensus statement of the European Heart Rhythm Association of the European Society of Cardiology. EP Europace. 27(8). 10 indexed citations
2.
Benz, Alexander P., Stefan H. Hohnloser, John W. Eikelboom, et al.. (2023). Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation. European Heart Journal. 44(20). 1807–1814. 23 indexed citations
3.
Blomström‐Lundqvist, Carina, et al.. (2023). Effect of dronedarone vs. placebo on atrial fibrillation progression: apost hocanalysis from ATHENA trial. EP Europace. 25(3). 845–854. 10 indexed citations
4.
Buckley, Benjamin J. R., Deirdre A. Lane, Peter Calvert, et al.. (2022). Effectiveness and Safety of Apixaban in over 3.9 Million People with Atrial Fibrillation: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine. 11(13). 3788–3788. 12 indexed citations
5.
Caterina, Raffaele De, Dimitar Raev, Shamir R. Mehta, et al.. (2020). Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI. The American Journal of Medicine. 133(11). 1302–1312. 3 indexed citations
6.
Heijman, Jordi, Stefan H. Hohnloser, & A. John Camm. (2020). Antiarrhythmic drugs for atrial fibrillation: lessons from the past and opportunities for the future. EP Europace. 23(Supplement_2). ii14–ii22. 28 indexed citations
7.
Hohnloser, Stefan H., A. John Camm, Riccardo Cappato, et al.. (2018). Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE‐AF study.. Clinical Cardiology. 41(4). 440–449. 8 indexed citations
8.
Mauri, Laura, Deepak L. Bhatt, Stefan H. Hohnloser, et al.. (2018). P3180The effect of PCI complexity on the efficacy and safety of dabigatran dual therapy vs warfarin triple therapy in atrial fibrillation: a subgroup analysis from the RE-DUAL PCI trial. European Heart Journal. 39(suppl_1). 1 indexed citations
9.
Brambatti, Michela, Stuart J. Connolly, Michael R. Gold, et al.. (2014). Temporal Relationship Between Subclinical Atrial Fibrillation and Embolic Events. Circulation. 129(21). 2094–2099. 444 indexed citations breakdown →
10.
Hijazi, Ziad, Jonas Oldgren, Ulrika Andersson, et al.. (2012). Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation. Circulation. 125(13). 1605–1616. 304 indexed citations
11.
12.
Aliot, Etienne, Alessandro Capucci, Stuart J. Connolly, et al.. (2011). Celivarone for Maintenance of Sinus Rhythm and Conversion of Atrial Fibrillation/Flutter. Journal of Cardiovascular Electrophysiology. 23(5). 462–472. 8 indexed citations
13.
Talajic, Mario, Paul Khairy, Sylvie Lévesque, et al.. (2010). Maintenance of Sinus Rhythm and Survival in Patients With Heart Failure and Atrial Fibrillation. Journal of the American College of Cardiology. 55(17). 1796–1802. 98 indexed citations
14.
Healey, Jeff S., Stuart J. Connolly, Michael R. Gold, et al.. (2010). The Relationship Between Atrial High-Rate Episodes and Stroke: The Asymptomatic Stroke and Atrial Fibrillation Evaluation in Pacemaker Patients (ASSERT) Trial. Data Archiving and Networked Services (DANS).
15.
Duray, Gábor Zoltán, Joachim R. Ehrlich, & Stefan H. Hohnloser. (2009). Dronedarone: a novel antiarrhythmic agent for the treatment of atrial fibrillation. Current Opinion in Cardiology. 25(1). 53–58. 6 indexed citations
16.
Israel, Carsten W., Giuseppe Boriani, Johan Brandt, et al.. (2006). P1-72. Heart Rhythm. 3(5). S131–S131. 1 indexed citations
17.
Grönefeld, Gerian & Stefan H. Hohnloser. (2003). Heart Failure Complicated by Atrial Fibrillation: Mechanistic, Prognostic, and Therapeutic Implications. Journal of Cardiovascular Pharmacology and Therapeutics. 8(2). 107–113. 27 indexed citations
18.
Klingenheben, Thomas, Gerian Grönefeld, Yi‐Gang Li, & Stefan H. Hohnloser. (2001). Effect of metoprolol and d,l-sotalol on microvolt-level T-wave alternans. Journal of the American College of Cardiology. 38(7). 2013–2019. 77 indexed citations
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by William G. Stevenson Breakdown of academic impact, for papers by Stuart J. Connolly Breakdown of academic impact, for papers by Prashanthan Sanders Breakdown of academic impact, for papers by Paulus Kirchhof Breakdown of academic impact, for papers by Günter Breithardt Breakdown of academic impact, for papers by Hans‐Christoph Diener Breakdown of academic impact, for papers by Cynthia M. Tracy Breakdown of academic impact, for papers by Jonathan P. Piccini Breakdown of academic impact, for papers by Jonathan M. Kalman Breakdown of academic impact, for papers by Katherine T. Murray
Rankless by CCL
2026